Tarsus Pharmaceuticals Inc.

Cargo Therapeutics’ decision to end all development for its allogeneic cell therapy technology platform and its cancer cell therapy candidates is not the kind of news the biopharmaceutical sector need

Valneva SE and Pfizer Inc. have consolidated their pole position in the race to get a Lyme disease vaccine to market with fresh data that show the potential benefit of a second booster dose in tack

Just over a year since its first US Food and Drug Administration approval and Tarsus Pharmaceuticals Inc. can look back with some satisfaction on its market debut for the Demodex blepharitis therapy

A lot of biopharmaceutical companies have changed their strategies during the past year or two with investors less receptive to stock offerings in 2022 and 2023 than they were in the two prior years,